Publications

  1. Ma WW, Xie H, Fetterly G, Pitzonka L, Whitworth A, LeVea C, Wilton J, Mantione K, Schihl S, Dy GK, Boland P, Iyer R, Tan W, Brady W, Straubinger RM, Adjei AA. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol. 2019 Feb; 42 (2):184-189
    View PubMed
  2. Ogden JR, Xie H, Ma WW, Hubbard JM. The Management of Older Adults with Pancreatic Adenocarcinoma. Geriatrics (Basel). 2018 Nov 26; 3 (4)
    View PubMed
  3. Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C, Cancer Genome Atlas Research Network. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep. 2018 Apr 3; 23 (1):194-212.e6
    View PubMed
  4. Rosen LS, LoRusso P, Ma W, Goldman JW, Weise A, Colevas AD, Adjei A, Yazji S, Shen A, Johnston S, Hsieh HJ, Chan IT, Sikic BI. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Invest New Drugs. 2016 Jul 16;
    View PubMed
  5. Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Ma W, Reni M, Harris M, Whorf R, Liu H, Li JS, Manax V, Romano A, Lu B, Goldstein D. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Br J Cancer. 2016 Jul 12; 115: (2)188-94.
    View PubMed
  6. Mei L, Du W, Ma W. Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises. J Gastrointest Oncol. 2016 Jun; 7: (3)487-94.
    View PubMed
  7. Roy Chaudhuri T, Straubinger NL, Pitoniak RF, Hylander BL, Repasky EA, Ma W, Straubinger RM. Tumor-Priming Smoothened Inhibitor Enhances Deposition and Efficacy of Cytotoxic Nanoparticles in a Pancreatic Cancer Model. Mol Cancer Ther. 2016 Jan; 15: (1)84-93.
    View PubMed
  8. Cohen SJ, Zalupski MM, Conkling P, Nugent F, Ma W, Modiano M, Pascual R, Lee FC, Wong L, Hersch E. A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naïve Pancreatic Adenocarcinoma. Am J Clin Oncol.2015 Dec 24;
  9. O'Neil BH, Scott AJ, Ma W, Cohen SJ, Leichman L, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler L, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol. 2015 Sep; 26 (9):1923-9 Epub 2015 June 19
    View PubMed
  10. Oyasiji T, Ma W. Novel adjuvant therapies for pancreatic adenocarcinoma. J Gastrointest Oncol. 2015 Aug; 6: (4)430-5.
    View PubMed
  11. Ma W. Current management of pancreatic cancer. The International Journal of Targeted Therapies in Cancer.;().
  12. Infante JR, Benhadji KA, Dy GK, Fetterly G, Ma W, Bendell J, Callies S, Adjei AA. Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors. Invest New Drugs. 2015 Apr; 33: (2)432-9.
    View PubMed
  13. Puzanov I, Sosman J, Santoro A, Saif MW, Goff L, Dy GK, Zucali P, Means-Powell JA, Ma W, Simonelli M, Martell R, Chai F, Lamar M, Savage RE, Schwartz B, Adjei AA. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. Invest New Drugs. 2015 Feb; 33: (1)159-68.
    View PubMed
  14. Ngamphaiboon N, Dy GK, Ma W, Zhao Y, Reungwetwattana T, DePaolo D, Ding Y, Brady W, Fetterly G, Adjei AA. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors. Invest New Drugs. 2015 Feb; 33: (1)225-32.
    View PubMed
  15. Eng JW, Reed CB, Kokolus KM, Pitoniak R, Utley A, Bucsek MJ, Ma W, Repasky EA, Hylander BL. Housing temperature-induced stress drives therapeutic resistance in murine tumour models through beta2-adrenergic receptor activation. Nat Commun. 2015; 6:6426.
    View PubMed
  16. Eng JW, Kokolus KM, Reed CB, Hylander BL, Ma W, Repasky EA. A nervous tumor microenvironment: the impact of adrenergic stress on cancer cells, immunosuppression, and immunotherapeutic response. Cancer Immunol Immunother. 2014 Nov; 63: (11)1115-28.
    View PubMed
  17. Tempero MA, Malafa MP, Behrman SW, Benson AB 3rd, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma W, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014 Aug; 12: (8)1083-93.
    View PubMed
  18. Devriese LA, Koch KM, Mergui-Roelvink M, Matthys GM, Ma W, Robidoux A, Stephenson JJ, Chu QS, Orford KW, Cartee L, Botbyl J, Arya N, Schellens JH. Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours. Invest New Drugs. 2014 Jun; 32: (3)481-8.
    View PubMed
  19. Zhang H, Hylander BL, LeVea C, Repasky EA, Straubinger RM, Adjei AA, Ma W. Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models. Br J Cancer. 2014 Jan 21; 110: (2)320-9.
    View PubMed
  20. Yang GY, Malik NK, Chandrasekhar R, Ma W, Flaherty L, Iyer R, Kuvshinoff B, Gibbs J, Wilding G, Warren G, May KS. Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer. J Gastrointest Oncol. 2013 Dec; 4: (4)361-9.
    View PubMed
  21. Ma W. LDK378: a promising next-generation ALK inhibitor with FDA Breakthrough Therapy designation. The International Journal of Targeted Therapies in Cancer.;()47-9.
  22. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma W, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31; 369: (18)1691-703.
    View PubMed
  23. Ma W, Hidalgo M. The winning formulation: the development of paclitaxel in pancreatic cancer. Clin Cancer Res. 2013 Oct 15; 19: (20)5572-9.
    View PubMed
  24. Bowles DW, Ma W, Senzer N, Brahmer JR, Adjei AA, Davies M, Lazar AJ, Vo A, Peterson S, Walker L, Hausman D, Rudin CM, Jimeno A. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br J Cancer. 2013 Sep 3; 109: (5)1085-92.
    View PubMed
  25. Dy GK, Infante JR, Eckhardt SG, Novello S, Ma W, Jones SF, Huff A, Wang Q, Suttle AB, Ottesen LH, Adjei AA, Burris HA 3rd. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib. Invest New Drugs. 2013 Aug; 31: (4)891-9.
    View PubMed
  26. Infante JR, Novello S, Ma W, Dy GK, Bendell JC, Huff A, Wang Q, Suttle AB, Allen R, Xu CF, Ottesen LH, Burris HA 3rd, Adjei AA. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors. Invest New Drugs. 2013 Aug; 31: (4)927-36.
    View PubMed
  27. Sher T, Bhat S, Jitawatanarat P, Desai N, Qiu J, Ma WW. Multiple myeloma mimicking metastatic pancreas cancer. J Clin Oncol. 2013 Jun 20; 31: (18)e297-9.
    View PubMed
  28. Jitawatanarat P, Wee W, Ma W. Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib. J Gastrointest Oncol. 2013 Jun; 4: (2)231-8.
    View PubMed
  29. Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander BH, Repasky EA, Ma W, Jusko WJ. Physiologically based pharmacokinetic models for everolimus and sorafenib in mice. Cancer Chemother Pharmacol. 2013 May; 71: (5)1219-29.
    View PubMed
  30. Pawaskar DK, Straubinger RM, Fetterly GJ, Ma W, Jusko WJ. Interactions of everolimus and sorafenib in whole blood lymphocyte proliferation. Pharm Res. 2013 Mar; 30: (3)707-13.
    View PubMed
  31. Weekes CD, Von Hoff DD, Adjei AA, Leffingwell DP, Eckhardt SG, Gore L, Lewis KD, Weiss GJ, Ramanathan RK, Dy GK, Ma W, Sheedy B, Iverson C, Miner JN, Shen Z, Yeh LT, Dubowy RL, Jeffers M, Rajagopalan P, Clendeninn NJ. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 1; 19: (5)1232-43.
    View PubMed
  32. Ma W. Nab-paclitaxel plus gemcitabine in pancreatic cancer. The International Journal of Targeted Therapies in Cancer.;()38-41.
  33. Pawaskar DK, Straubinger RM, Fetterly GJ, Ma W, Jusko WJ. Interactions of everolimus and sorafenib in pancreatic cancer cells. AAPS J. 2013 Jan; 15: (1)78-84.
    View PubMed
  34. Fora AA, McMahon JA, Wilding G, Groman A, Ma W, Romano KS, Fakih MG. A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan. Oncology. 2013; 84: (4)210-3.
    View PubMed
  35. Malik NK, May KS, Chandrasekhar R, Wee W, Ma W, Flaherty L, Iyer R, Gibbs J, Kuvshinoff B, Wilding G, Warren G, Yang GY. Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. J Gastrointest Oncol. 2012 Dec; 3: (4)326-34.
    View PubMed
  36. Dewanwala A, Kotowski A, LeVea CM, Ma W. Secondary Tumors of the Pancreas: Case Report and a Single-Center Experience. J Gastrointest Cancer. 2012 Sep; 43 Suppl 1:S117-24.
    View PubMed
  37. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB 3rd, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma W, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA, National Comprehensive Cancer Networks. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012 Jun 1; 10: (6)703-13.
    View PubMed
  38. Ma W, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C, Maniar M, Wilhelm F, Eckhardt SG, Adjei AA, Jimeno A. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. Clin Cancer Res. 2012 Apr 1; 18: (7)2048-55.
    View PubMed
  39. Shao H, Gao C, Tang H, Zhang H, Roberts LR, Hylander BL, Repasky EA, Ma WW, Qiu J, Adjei AA, Dy GK, Yu C. Dual targeting of mTORC1C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo. J Hepatol. 2012 Jan; 56: (1)176-83.
    View PubMed
  40. Ma W. Development of focal adhesion kinase inhibitors in cancer therapy. Anticancer Agents Med Chem. 2011 Sep; 11: (7)638-42.
    View PubMed
  41. Kotowski A, Ma W. Emerging therapies in pancreas cancer. J Gastrointest Oncol. 2011 Jun; 2: (2)93-103.
    View PubMed
  42. Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC, Zhao M, Rajeshkumar NV, Jimeno A, Donehower R, Iacobuzio-Donahue C, Barrett M, Rudek MA, Rubio-Viqueira B, Laheru D, Hidalgo M. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer. 2010 Aug 24; 103(5):649-55. Epub 2010 Jul 27.
    View PubMed
  43. May KS, Khushalani NI, Chandrasekhar R, Wilding GE, Iyer RV, Ma W, Flaherty L, Russo RC, Fakih M, Kuvshinoff BW, Gibbs JF, Javle MM, Yang GY. Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomen. Int J Radiat Oncol Biol Phys. 2010 Mar 15; 76: (4)1193-8.
    View PubMed
  44. Ma W, Herman JM, Jimeno A, Laheru D, Messersmith WA, Wolfgang CL, Cameron JL, Pawlik TM, Donehower RC, Rudek MA, Hidalgo M. A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. Transl Oncol. 2010; 3: (6)373-9.
    View PubMed
  45. Ma W, Jacene H, Song D, Vilardell F, Messersmith WA, Laheru D, Wahl R, Endres C, Jimeno A, Pomper MG, Hidalgo M. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol. 2009 Jun 1; 27: (16)2697-704.
    View PubMed
  46. Ma W, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009 Mar-Apr; 59: (2)111-37.
    View PubMed
  47. Jimeno A, Rudek MA, Kulesza P, Ma W, Wheelhouse J, Howard A, Khan Y, Zhao M, Jacene H, Messersmith WA, Laheru D, Donehower RC, Garrett-Mayer E, Baker SD, Hidalgo M. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol. 2008 Sep 1; 26: (25)4172-9.
    View PubMed
  48. Jimeno A, Messersmith WA, Lee CK, Ma W, Laheru D, Donehower RC, Baker SD, Hidalgo M. Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies. Ann Oncol. 2008 Feb; 19: (2)374-9.
    View PubMed
  49. Ma W. Sorafenib and Hepatocellular Carcinoma. Hospital Pharmacy Europe.;(36).
  50. Ma W, Hidalgo M. Exploiting novel molecular targets in gastrointestinal cancers. World J Gastroenterol. 2007 Nov 28; 13: (44)5845-56.
    View PubMed
  51. Ma W, Jimeno A. Temsirolimus. Drugs Today (Barc). 2007 Oct; 43: (10)659-69.
    View PubMed
  52. Ma W, Jimeno A. Strategies for suppressing angiogenesis in gynecological cancers. Drugs Today (Barc). 2007 Apr; 43: (4)259-73.
    View PubMed
  53. Ma W, Messersmith WA. Palliation of Colorectal Cancer - New Possibilities and Challenges: Commentary. Oncology.;21(5)566-77.
  54. Ma W, Messersmith WA. CEA monitoring in colorectal cancer: commentary. Oncology.;20(6)588-94.